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Severe  maternal  complications  in pregnancy  in  sub-Saharan  Africa  contribute  to  high  maternal  mortality
and  morbidity.  Incidence  data  on  severe  maternal  complications,  life-threatening  conditions,  maternal
deaths  and  birth  outcomes  are  essential  for clinical  audit  and  to inform  trial design  of the  types  and
frequency  of  expected  severe  adverse  events  (SAEs).  However,  such  data  are  very  limited,  especially  in
sub-Saharan  Africa.  We  set  up  standardized,  systematic  clinical  surveillance  embedded  into  routine  clin-
ical care  in  a rural  county  hospital  in Kenya.  Pregnant  women  and  newborns  are systematically  assessed
and  investigated.  Data  are  reported  using  a standardized  Maternal  Admission  Record  that  forms  both  the
hospital’s  clinical  record and  the  data  collection  tool.  Integrating  clinical  surveillance  with  routine  clinical
care  is  feasible  and  should  be expanded  in  sub-Saharan  Africa,  both  for  improving  clinical  practice  and
as a basis  for  intervention  studies  to  reduce  maternal  and  newborn  mortality  and morbidity  where  rates
are highest.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
The burden of maternal mortality in sub-Saharan Africa (sSA)
emains high. In Kenya, in 2013, the estimated maternal mortality
atio (MMR)  was 277 (175–414) per 100,000 [1], which corre-
ponded to an estimated 4361 (2759–6514) maternal deaths [1]
cross over 4700 health facilities [2].
Maternal deaths are the ‘tip of the iceberg’ of the 20–30 fold
ore women who  experience severe maternal morbidity [3]. This
ncludes women with a “near miss” or life threatening complication
signs of organ dysfunction as a result of a severe complication at
elivery) [4], severe maternal complications (severe post-partum
aemorrhage, severe pre-eclampsia, eclampsia, sepsis or severe
ystemic infection, ruptured uterus, and severe complications of
ermination of pregnancy) [5]. In addition, there are many less
evere conditions which impact on maternal health and wellbeing
nd are not currently well-deﬁned or measured [3]. In a recent
ystematic review, including facility based studies in Africa, life-
hreatening conditions (LTCs) occurred in 0.4–0.8% of all deliveries
∗ Corresponding author at: KEMRI-Wellcome Trust Research Programme, PO Box
30, Kiliﬁ 80108, Kenya. Tel.: +254  709 983000.
E-mail address: aseale@nhs.net (A.C. Seale).
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
[6], although accurate data were available from only three stud-
ies [7–9]. Severe maternal complications [4], ranged more widely:
from 0.6% to 15% of deliveries [6], based on limited data from
another three studies [10–12]. Less severe conditions are not usu-
ally reported at all, but tools to identify these in resource-poor
settings are proposed by the WHO  Maternal Morbidity Working
Group [3].
Improving health information systems [13], with clinical
surveillance and data collection at health facilities needs both polit-
ical and ﬁnancial support. Integrating clinical surveillance into
routine clinical care, and engagement and ownership of the system
by health facility staff can help reduce costs and ensure systems are
supported.
At present, the limited data make it difﬁcult to estimate the bur-
den of maternal mortality and morbidity, as well as past trends.
We  do not know whether variations in incidence are due to chance
(particularly for relatively rare events such as deaths), differences
in reporting (for example in deﬁnitions), or other factors, such as
ability to access care, variations in co-morbidities in the popula-
tion (such as HIV infection), and/or the clinical care available in the
health facility.
Structured medical records can support clinical care as an
“aide-memoire” of key clinical items and provide a standard-
ized framework for data collection. These data themselves then
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Supplementary data associated with this article can be found, in
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acilitate clinical audit to ensure standards of care are met. In
ddition, the data provide a platform for research studies and can
nform the design and conduct of clinical trials. Background data on
aternal mortality and morbidity inform trial safety monitoring in
erms of expected frequencies of Severe Adverse Events (SAEs) and
dverse Events (AEs) in phase II and III trials. Furthermore, if and
hen vaccines given during pregnancy are rolled out, systems will
e needed for phase IV surveillance for events which may  or may
ot be associated with vaccines.
This paper aims to describe the methods undertaken to achieve
ystematic clinical surveillance in the maternity department of a
ural county hospital in Kenya, in close collaboration with hospital
anagement, and involving all hospital staff providing maternity
are. The purpose of the surveillance was to support clinical care,
nsure staff engagement and sustainability, inform clinical audit,
nd provide a platform for research and inform future clinical trials.
. Methods
Kiliﬁ County Hospital (KCH) is a government run county hospital
n rural Kenya, with around 4000 deliveries per year. KCH provides
omprehensive emergency obstetric and neonatal care, including:
ntrapartum (e.g. instrumental deliveries (vacuum) and Caesarean
ections) and postpartum (e.g. removal of retained placentas and
roducts of conception) procedures; basic new-born resuscitation
hen clinically indicated; blood transfusion, and basic care activi-
ies (e.g. administration of intravenous (IV) antibiotics, uterotonic
rugs (e.g. oxytocin), and IV anticonvulsants).
All mothers who present in labour are registered on admission
y ﬁeldworkers based in the maternity ward 24 h a day, seven days
 week. Clinical data are documented by government-employed
urses who then complete a structured maternal admission record
MAR). The form (see supplementary web annexe) was developed
nd piloted with clinical staff, and there has been on-going devel-
pment with support from research staff, who are available on a
aily basis to discuss amendments and improvements. The MAR
ncludes antenatal history, delivery details, partogram (the national
tandard) and maternal problems before discharge as well as new-
orn outcomes. Examination is structured and includes routine
bservations (respiratory rate, heart rate, temperature, blood pres-
ure) as well as symphyseal-fundal height, cervical assessment and
eneral examination. Investigations for clinical purposes that are
outinely taken on admission include a full blood count and two
oint of care tests: a rapid test for malaria infection and a urine
ipstick for proteinuria and nitrites. Rapid HIV testing is offered if
he woman has not been tested in the current pregnancy, according
o national guidelines.
. Results
Clinical surveillance is fully integrated into clinical care in the
CH maternity department. Details of 16,728 maternal admissions
ave been recorded from 1st January 2011 to 31st December 2014.
he numbers of annual maternal admissions have been increasing
3651 in 2011 to 5572 in 2014), possibly in part because deliv-
ry fees ceased to be charged in 2013. Clinical assessment and
ocumentation are undertaken by nursing and medical staff as
art of routine care. Changes in nursing, medical staff and hospital
anagement have occurred, and been associated with transient
ncreases in missing data (between 1% and 18% of data points
re missing). However, once embedded, surveillance systems have
een integrated into care and maintained. The data from MARs have
acilitated regular discharge reports, clinical audits and provided a
latform for studies of precise rates of adverse events, which will
e submitted for publication. Recent and ongoing research studies (2015) 6466–6468 6467
include studies of risk factors for adverse maternal and adverse
perinatal outcomes, the clinical and molecular epidemiology of
Group B Streptococcus, and INTERBIO-21st assessing the effects of
adverse intrauterine environment on foetal growth (http://www.
interbio21.org.uk/).
4. Discussion
Routine surveillance of maternal admissions for delivery can be
integrated into clinical care and sustained by becoming established
as the working ‘culture’. Data can be used to inform clinical practice
(through audit), as a platform for research studies, and as a rich data
source for maternal vaccine trials.
Maternal vaccines in development, such as those for Group B
Streptococcus [14] and respiratory syncytial virus (RSV) could sub-
stantially reduce the burden of maternal and neonatal infection,
building on the maternal tetanus vaccination programme in sSA
[15,16]. Maternal vaccination, however, presents special concerns
both for the safety of study participants [17], and for ongoing phase
IV monitoring if the vaccine is subsequently introduced. In other
settings, retrospective maternal data to establish safety have been
used as a comparison group, following vaccine introduction, for
example in the USA and the UK following the introduction of mater-
nal pertussis vaccination [18,19]. Surveillance systems in sSA are
inadequate to provide these data at present, despite the need for
interventions to be introduced safely and, if effective, at scale.
We have established a successful model for integrating stan-
dardized clinical surveillance with routine clinical care. It is needed
in more health facilities in sSA, both for clinical practice, for our
understanding of maternal health, and to inform and trial pre-
ventive methods to reduce the burden of maternal mortality and
morbidity where rates are highest.
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